Statement - Zantac (ranitidine) litigation

GSK

PUBLISHED JUN 23, 2023 BY GSK

For media and investors only

GSK plc (LSE/NYSE: GSK) today confirmed it has reached a confidential settlement with James Goetz, and the case he filed in California state court, set to begin trial on July 24, 2023, will be dismissed. The settlement reflects the Company's desire to avoid distraction related to protracted litigation in this case. GSK does not admit any liability in this settlement and will continue to vigorously defend itself based on the facts and the science in all other Zantac cases.

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at <u>gsk.com</u>.

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include but are not limited to those described under Item 3.D 'Risk factors" in the company's Annual Report on Form 20-F for 2022, GSK's Q1 Results for 2023 and any impacts of the COVID-19 pandemic.

Press release distributed by Wire Association on behalf of GSK, on Jun 23, 2023. For more information subscribe and follow us.

Media Assets

Embedded Media

Visit the online press release to interact with the embedded media.

https://wireassociation.eu/newsroom/gsk/releases/en/statement-zantac-ranitidine-litigation-1758

GSK

Newsroom: https://wireassociation.eu/newsroom/gsk

Website: https://www.gsk.com/

Primary Email: corporate.media@gsk.com

Social Media

Facebook - https://www.facebook.com/GSK

Twitter - http://twitter.com/GSK

Youtube - http://www.youtube.com/GSK

Linkedin - http://www.linkedin.com/company/glaxosmithkline

Instagram - https://www.instagram.com/gsk/